Ilkowski I Partnerzy sp.p. Lekarzy — Clinical Trial Site

31 Registered trials

8 Currently recruiting

Organisation

Ilkowski I Partnerzy sp.p. Lekarzy

Location

Poznan, Poland

Identifier

ORG-100043457

Address

Ul. Wierzbowa 2/2, 61-853, Poland

Departments

#40605: Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD
301-118: NZOZ NEURO-KARD Ilkowski i Partnerzy Spółka Partnerska Lekarzy
Chronic pain
N/A
NA
Neurology
Niepubliczny Zaklad Opieki Zdrowotnej Neuro-Kard
NZOZ NEURO- KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
NZOZ Neuro-Kard
NZOZ Neuro-Kard Ilkowski i Partnerzy sp.p. Lekarzy
Nzoz Neuro-Kard Ilkowski i Partnerzy SPL
NZOZ NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
NZOZ NEURO-KARD Ilkowski i Partnerzy Spółka Partnerska Lekarzy
NZOZ Neuro-Kard Ilkowski Partnerzy Spółka Partnerska Lekarzy
unknown

Clinical trials at this site (31)

Search interface

A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gr… Recruiting

2025-522406-20-00 Generalized Myasthenia Gravis and Ocular Myasthenia Gra 9 2026-06-15
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting

2024-512126-29-00 Generalized Myasthenia Gravis 5 2025-02-25
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P… Recruiting

2024-514617-35-00 Progressive forms of Multiple Sclerosis 4 2021-12-20
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Recruiting

2025-523950-15-01 Generalized Myasthenia Gravis 4 2026-05-29
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting

2025-523757-33-00 multiple sclerosis 4 2026-05-07
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Relapsing multiple sclerosis 5 2025-06-18
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Upper limb spasticity after stroke or traumatic brain i 7 2021-04-29
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5) Ended

2025-522340-40-00 Alzheimer Disease Dementia Brain Diseases Central 5 2025-12-04
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Myasthenia Gravis 1 2024-05-15
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Ended

2023-506127-29-00 Diabetic Peripheral Neuropathy 4 2024-03-05
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514619-88-00 Relapsing Multiple Sclerosis 5 2022-03-18
An extension study to learn if Zilucoplan is safe and works over a long period in adult participants with generalized myasthenia gravis. Ended

2024-512399-37-00 Generalized Myasthenia Gravis 5 2020-12-29
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502618-95-00 Relapsing multiple sclerosis (RMS) 5 2020-11-24
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Ended

2024-516680-91-00 relapsing multiple sclerosis 5 2020-05-21
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended

2024-513435-24-01 Neuropathic Pain; Distal Sensory Polyneuropathy 4 2025-06-03
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
A study to learn if a Zilucoplan auto-injector is safe and works in adults with myasthenia gravis Ended

2023-508287-30-00 Generalized Myasthenia Gravis 5 2024-08-29
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01